, Tracking Stock Market Picks
Enter Symbol:
Acorda Therapeutics, Inc. (ACOR) [hlAlert]

up 3.15 %

Acorda Therapeutics, Inc. (ACOR) upgraded to Outperform with price target $30 by FBR Capital

Posted on: Friday,  Nov 1, 2013  8:25 AM ET by FBR Capital

FBR Capital rated Outperform Acorda Therapeutics, Inc. (NASDAQ: ACOR) on 11/01/2013, when the stock price was $30.72. Since
then, Acorda Therapeutics, Inc. has gained 3.16% as of 01/26/2016's recent price of $31.69.
If you would have followed this FBR Capital's recommendation on ACOR, you would have gained 3.15% of your investment in 816 days.

Acorda Therapeutics is commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system. Acorda currently markets Zanaflex Capsules for the management of spasticity. The Company's lead product candidate, Fampridine-SR, for the improvement of walking ability in persons with multiple sclerosis. It develops therapies that restore neurological function to people with spinal cord injury, multiple sclerosis and related conditions of the nervous system.

FBR Capital uses a highly disciplined analysis focused on intrinsic value, which we developed to critically examine the capital structure of the companies we cover, as well as their competitive positions and the growth opportunities within their industries. We apply this discipline – which helps us assess how effectively a company’s managers deploy the capital entrusted to them – not only in our published research but also when making investing and underwriting judgments.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/1/2013 8:25 AM Buy
30.72 30.00
as of 12/13/2013
1 Week down  -5.73 %
1 Month down  -11.10 %
3 Months down  -3.09 %
1 YTD down  -3.09 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/30/2013 8:25 AM Hold
33.36 35.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy